SynthesisAdvances in therapy2021
Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.
Synthesis in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025Pooled it
- Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.International clinical psychopharmacology · 2025Pooled it
- Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial.International journal of environmental research and public health · 2022Trial
- Quality of Service and Cost of Managing an Episode of Major Depressive Disorder: A Cohort Study in Iran.Archives of Iranian medicine · 2026Article
- Responsiveness and minimal important differences of common disability measures in people with depression and anxiety disorders.Frontiers in rehabilitation sciences · 2025Article
- Agomelatine Transdermal System Product Cycle: Development, Material/ Process Screening, Optimization, Characterization, Delivery Mechanics and Irritation study on Rat.Recent advances in drug delivery and formulation · 2025Article
- Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.Brain sciences · 2023Review
- Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine.Neurology and therapy · 2023Article
- Anxiety Symptoms in Depression: Contemporary Treatment Approaches.Neurology and therapy · 2023Article
- Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action.Therapeutic advances in psychopharmacology · 2022Review
- The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021Article
- Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine.Advances in therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe purpose of this study is to investigate the effects of agomelatine on anxious symptoms and functional impairment in a pooled dataset from randomized placebo-controlled trials for generalized anxiety disorder (GAD).
methodsData from three randomized, placebo-controlled trials that evaluated the efficacy of agomelatine 25-50 mg were pooled. The short-term (12 weeks) efficacy of agomelatine was assessed in regards to (1) anxious symptoms using the Hamilton Anxiety Scale (HAM-A), and (2) functional impairment using the Sheehan Disability Scale (SDS). Meta-analysis using a random effect model was used to assess differences between groups. Remission and response rates for the HAM-A and SDS were calculated, and analyses were repeated in participants with more severe anxiety symptoms.
resultsIn total, 669 patients (340 on agomelatine; 329 on placebo) were included in the analyses. Compared to placebo, the agomelatine group had a significant reduction in HAM-A total score at week 12 (between group difference: 6.30 ± 2.51, p = 0.012). Significant effects were also found for symptom response on the HAM-A (67.1% of patients on agomelatine vs. 32.5% on placebo) and symptom remission (38.8% of patients on agomelatine vs. 17.3% on placebo). Compared to placebo, there was a significant difference in favour of the agomelatine group at week 12 on the SDS total score (5.11 ± 1.81, p = 0.005). Significant effects were also found for functional response on the SDS (79.1% of patients on agomelatine vs. 43.2% of placebo) and functional remission (55.2% of patients on agomelatine vs. 25.4% on placebo). All findings for anxious symptoms and functional impairment were confirmed in the subset of more severely anxious patients. Agomelatine was well tolerated by patients.
conclusionThis meta-analysis confirms that agomelatine reduces anxiety symptoms and improves the global functioning of GAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.